BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 27034004)

  • 1. Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer.
    Li W; Zhai L; Wang H; Liu C; Zhang J; Chen W; Wei Q
    Oncotarget; 2016 May; 7(19):27778-86. PubMed ID: 27034004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exosome-mediated transfer of lncRNA‑SNHG14 promotes trastuzumab chemoresistance in breast cancer.
    Dong H; Wang W; Chen R; Zhang Y; Zou K; Ye M; He X; Zhang F; Han J
    Int J Oncol; 2018 Sep; 53(3):1013-1026. PubMed ID: 30015837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer.
    Shi SJ; Wang LJ; Yu B; Li YH; Jin Y; Bai XZ
    Oncotarget; 2015 May; 6(13):11652-63. PubMed ID: 25871474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of LncRNA GAS5 promotes liver cancer proliferation and drug resistance by decreasing PTEN expression.
    Wang C; Ke S; Li M; Lin C; Liu X; Pan Q
    Mol Genet Genomics; 2020 Jan; 295(1):251-260. PubMed ID: 31705194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exosome-mediated lncRNA AFAP1-AS1 promotes trastuzumab resistance through binding with AUF1 and activating ERBB2 translation.
    Han M; Gu Y; Lu P; Li J; Cao H; Li X; Qian X; Yu C; Yang Y; Yang X; Han N; Dou D; Hu J; Dong H
    Mol Cancer; 2020 Feb; 19(1):26. PubMed ID: 32020881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The GAS5/miR-222 Axis Regulates Proliferation of Gastric Cancer Cells Through the PTEN/Akt/mTOR Pathway.
    Li Y; Gu J; Lu H
    Dig Dis Sci; 2017 Dec; 62(12):3426-3437. PubMed ID: 29098549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GAS5 knockdown reduces the chemo-sensitivity of non-small cell lung cancer (NSCLC) cell to cisplatin (DDP) through regulating miR-21/PTEN axis.
    Cao L; Chen J; Ou B; Liu C; Zou Y; Chen Q
    Biomed Pharmacother; 2017 Sep; 93():570-579. PubMed ID: 28686971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of autophagy induced by PTEN loss promotes intrinsic breast cancer resistance to trastuzumab therapy.
    Ning L; Guo-Chun Z; Sheng-Li A; Xue-Rui L; Kun W; Jian Z; Chong-Yang R; Ling-Zhu W; Hai-Tong L
    Tumour Biol; 2016 Apr; 37(4):5445-54. PubMed ID: 26563373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of LncRNA TINCR by H3K27 acetylation promotes Trastuzumab resistance and epithelial-mesenchymal transition by targeting MicroRNA-125b in breast Cancer.
    Dong H; Hu J; Zou K; Ye M; Chen Y; Wu C; Chen X; Han M
    Mol Cancer; 2019 Jan; 18(1):3. PubMed ID: 30621694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
    Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
    BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non-coding RNA GAS5 antagonizes the chemoresistance of pancreatic cancer cells through down-regulation of miR-181c-5p.
    Gao ZQ; Wang JF; Chen DH; Ma XS; Yang W; Zhe T; Dang XW
    Biomed Pharmacother; 2018 Jan; 97():809-817. PubMed ID: 29112934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
    Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
    J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. lncRNA GAS5-promoted apoptosis in triple-negative breast cancer by targeting miR-378a-5p/SUFU signaling.
    Zheng S; Li M; Miao K; Xu H
    J Cell Biochem; 2020 Mar; 121(3):2225-2235. PubMed ID: 31692053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
    Ye XM; Zhu HY; Bai WD; Wang T; Wang L; Chen Y; Yang AG; Jia LT
    BMC Cancer; 2014 Feb; 14():134. PubMed ID: 24571711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells.
    Raina D; Uchida Y; Kharbanda A; Rajabi H; Panchamoorthy G; Jin C; Kharbanda S; Scaltriti M; Baselga J; Kufe D
    Oncogene; 2014 Jun; 33(26):3422-31. PubMed ID: 23912457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of Long Noncoding RNA GAS5 Inhibits Lung Cancer Cell Proliferation and Metastasis via miR-205/PTEN Axis.
    Dong L; Li G; Li Y; Zhu Z
    Med Sci Monit; 2019 Mar; 25():2311-2319. PubMed ID: 30926767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
    Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. lncRNA GAS5 restrains CCl
    Dong Z; Li S; Wang X; Si L; Ma R; Bao L; Bo A
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G539-G550. PubMed ID: 30735452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between long non-coding RNAs (lncRNAs) H19 expression and trastuzumab resistance in breast cancer.
    Sun Z; Zhang C; Wang T; Shi P; Tian X; Guo Y
    J Cancer Res Ther; 2019; 15(4):933-940. PubMed ID: 31436255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.